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Distress disorder (a collective term for generalized anxiety disorder and major depressive
disorder) is a well-known co-morbidity of bronchial asthma. The irisin—brain-derived
neurotrophic factor (BDNF) axis is a pathway that influences several neurobehavioral
mechanisms involved in the pathogenesis of distress disorder. Thus, the aim of the
present study was to quantify the serum irisin and BDNF concentrations in order
to investigate the possible link between the irisin/BDNF axis and distress disorder
in an asthma patient cohort. Data of 167 therapy-controlled asthma patients were
analyzed. Demographic, anthropometric, and anamnestic data were collected, routine
laboratory parameters supplemented with serum irisin and BDNF levels were determined,
pulmonary function test was performed using whole-body plethysmography, and quality
of life was quantified by means of the St. George’s Respiratory Questionnaire (SGRQ).
Correlation analysis as well as simple and multiple linear regression were used to assess
the relationship between the irisin level and the Impacts score of SGRQ, which latter is
indicative of the presence and severity of distress disorder. We have found a significant,
positive linear relationship between the Impacts score and the reciprocal of irisin level.
This association was stronger in patients whose BDNF level was higher, and it was
weaker (and statistically non-significant) in patients whose BDNF level was lower. Our
results indicate that higher serum irisin level together with higher serum BDNF level are
associated with milder (or no) distress disorder. This finding suggests that alteration of
the irisin/BDNF axis influences the presence and severity of distress disorder in asthma
patients.
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INTRODUCTION
Generalized anxiety disorder and major depressive disorder,
collectively termed distress disorder (Renna et al., 2017), are
well-known co-morbidities of bronchial asthma (referred to as
asthma hereinafter; Yang et al., 2016). The significance of distress
disorder in asthma symptom control, therapeutic adherence
and quality of life is well-established and underscored (Global
Initiative for Asthma, 2016). Increased prevalence of distress
disorder in asthma patients in comparison with that in the
general population is also recognized (Goodwin et al., 2003;
Global Initiative for Asthma, 2016; Porsbjerg and Menzies-
Gow, 2017). For example, analysis of data from the World
Mental Health Survey, a cross-national population-based survey
including 85,088 participants (of whom 42,697 self-reportedly
suffered from asthma), showed that age- and sex-adjusted odds
for depressive and anxiety disorders were 1.6 (CI: 1.4, 1.8) and
1.5 (CI: 1.4, 1.7), respectively, when patients with asthma were
compared to those without this disease (Scott et al., 2007).
Furthermore, a bidirectional relationship seems to exist between
asthma and distress disorder, supported by large prospective
studies showing robust association between mental disorders
in childhood and subsequent evolution of adult onset asthma
(Scott et al., 2007; Patten et al., 2008; Loerbroks et al., 2010;
Brunner et al., 2014). Conversely, emergence of respiratory
symptoms consistent with increased airway hyperreactivity or
asthma exacerbations were reported in relation to even transient
provocation of depressed or sad mood (Opolski and Wilson,
2005). This two-way relationship suggests the possibility for a
cause-and-effect relationship, and warrants the clarification of
plausible shared neurobiological pathways underlying this link
(Goodwin, 2016).
Recently, narrowed and rigid contextual learning was
proposed as a potential common neurobehavioral mechanism
that may underlie distress disorder (Renna et al., 2017).
Contextual learning is a basic mechanism involved in
reinforcement (reward) learning and motivation (Zsuga
et al., 2016a,b) to organize cues and their respective contexts
Abbreviations: ACOS, asthma-COPD overlap syndrome; apoA1, apolipoprotein
A1; apoB, apolipoprotein B; ATS, American Thoracic Society; BDNF, brain derived
neurotrophic factor; BTPS, body temperature and pressure saturated; CI, 95%
confidence interval; CK, creatine kinase; COPD, chronic obstructive pulmonary
disease; CRP, C-reactive protein; ELISA, enzyme-linked immunosorbent assay;
ERS, European Respiratory Society; FEF25-75% % pred, forced expiratory flow
between 25% and 75% of FVC, percent of predicted value; FEV1% pred, forced
expiratory volume in 1 second, percent of predicted value; FEV1/FVC% pred,
ratio of FEV1 to FVC (= FEV1% = Tiffeneau index), percent of predicted
value; FNDC5, fibronectin type III domain-containing protein 5; FVC% pred,
forced vital capacity, percent of predicted value; GINA, Global Initiative for
Asthma; GOT, glutamate-oxaloacetate transaminase; GPT, glutamate-pyruvate
transaminase; HDL, high-density lipoprotein; HgA1c, hemoglobin A1c (glycated
hemoglobin); HOMA, homeostasis model assessment; IQR, interquartile range;
LDH, lactate dehydrogenase; LDL, low-density lipoprotein; Lp(a), lipoprotein (a);
Raw, airway resistance; RV% pred, residual volume, percent of predicted value;
RV/TLC% pred, ratio of RV to TLC, percent of predicted value; SD, standard
deviation; SGRQ, St. George’s Respiratory Questionnaire; STROBE, strengthening
the reporting of observational studies in epidemiology; sTSH, thyroid-stimulating
hormone determined in a sensitive manner; TLC% pred, total lung capacity,
percent of predicted value; γGT, gamma-glutamyl transferase.
(including rewards) into context frames based on their statistical
regularities (Bar, 2007). These will serve as the starting point for
making forward looking simulations to maximize the sum of
future rewards and govern motivated behavior (for an overview
see Zsuga et al., 2016b). Characteristic symptoms such as
depressive rumination and anxiety have been directly linked
to the alteration of contextual learning (Bar, 2009) in distress
disorder.
One possible molecular pathway that may link affective
constructs (anxiety, rumination) to reinforcement learning is
the irisin—brain-derived neurotrophic factor (BDNF) axis, on
basis of its potential role in reinforcement learning, given
its modulatory effect in structures related to the generation
of context frames inherent of reinforcement learning (Zsuga
et al., 2016b). Irisin is a contraction-regulated myokine, a
highly conservative protein formed by proteolytic cleavage of
fibronectin type III domain-containing protein 5 (FNDC5)
(Boström et al., 2012). Expression of FNDC5/irisin is most
abundant in skeletal muscle and is enhanced by voluntary
exercise (Wrann et al., 2013). Upon its release into the systemic
circulation, irisin may cause browning of white adipose tissue
(Boström et al., 2012) and is able to cross the blood-brain barrier
(Phillips et al., 2014). Moreover its expression is substantial in the
central nervous system, e.g., midbrain and hippocampus (Phillips
et al., 2014), structures fundamentally involved in reinforcement
learning (Zsuga et al., 2016a,c). In the CNS irisin can induce the
expression of BDNF (Wrann et al., 2013).
BDNF is a neurotrophin that is involved in preserving the
plasticity of the brain (Chao et al., 2006) by inducing long-term
potentiation and consequent increase of the strength of synaptic
connections inherent of reward-related changes and subsequent
modified behavior (Yan et al., 2005). BDNF can bidirectionally
cross the blood-brain barrier by means of a high-capacity,
saturable transport system (Pan et al., 1998). Recently, our group
reported the alteration of the irisin/BDNF axis in mood disorders
accompanying chronic obstructive pulmonary disease (COPD)
(Papp et al., 2017). Others have shown the association of BDNF
gene polymorphism with anxiety and depression in asthma and
thus suggested that genetic variants may assume a significant
role in the pathogenesis of distress disorder in the context
of asthma (Yang et al., 2016). Furthermore, the importance
of BDNF genotype, by modulating the effect physical exercise
has on BDNF secretion was also shown in patients suffering
from mild cognitive impairment (Nascimento et al., 2015). This
finding further suggests the clinical significance of the potential
link between exercise-induced irisin production and consequent
BDNF production, pointing to irisin as the humoral mediator
linking exercise to BDNF.
Given previous preclinical findings clearly pointing to irisin
as the upstream mediator of hippocampal BDNF production
(Wrann et al., 2013), elucidation of this potential mechanism
in varying clinical settings is warranted. A plausible approach
is to investigate a clinical construct that is possibly under the
control of the irisin/BDNF axis. Based on findings of others
regarding altered contextual learning in distress disorder, a
process inherent of reinforcement learning, as well as prior
observations pertaining to the potential involvement of BDNF
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in mood disorders and anxiety (Latsko et al., 2016; Levada et al.,
2016; Cagni et al., 2017) assessing the presence and/or severity
of distress disorder is feasible. Due to the abundance of clinical
observations regarding the complex interplay between asthma
and distress disorder we set out to assess the potential interaction
between the irisin/BDNF axis and severity of distress disease in
our asthma patient cohort.
MATERIALS AND METHODS
Study Design and Protocol
This is a cross-sectional study of asthma patients (n = 163)
designed in compliance with the STROBE statement for cross-
sectional studies (Von Elm et al., 2007). The present study
adheres to the principles of the Declaration of Helsinki and
was initiated after the approval of the Ethical Committee of
the University of Debrecen (DEOEC RKEB/IKEB 3632-2012).
Written informed consent was obtained from each participant
prior to inclusion.
The recruitment period for the study was from September 1.
2012 to October 15. 2013. Consecutive patients attending the
outpatient unit of the Department of Pulmonology (University
of Debrecen) diagnosed with chronic inflammatory airway
diseases (asthma, COPD, ACOS, and allergic rhinitis) were
screened by pulmonologists blinded to the research hypothesis.
Exclusion criteria included history of malignant or benign
tumors, or presence of acute inflammation of any kind during
the precedingmonth. During the recruitment period 319 patients
were included (asthma: n = 167, COPD: n = 74, ACOS: n = 21,
allergic rhinitis: n= 56), using the same protocol.
The current study assesses the potential involvement of altered
irisin/BDNF axis in distress disorder among in our asthma cohort
(n = 167). All patients participated in a control-based asthma
management program complying with GINA as well as the
relevant Hungarian practice guideline (Boulet et al., 2012; Tamási
et al., 2012). Treatment at the time of inclusion was provided
as clinically warranted hence most patients were regularly
using inhaled corticosteroid preparations (n = 156) and/or
long-acting β2 agonists (n = 141). Corticosteroid therapy was
omitted only due to co-morbidities rendering the risks related
to this therapy higher than the accrued benefits. Demographic,
anthropometric, and anamnestic (including history of smoking,
diabetes, dyslipidemia, and hypertension) data were obtained.
Smoking exposure was characterized by pack-years (that
included past smoking and current smoking exposure). Disease-
specific quality of life was characterized by using the official
Hungarian version of the St. George’s Respiratory Questionnaire
(SGRQ) (Meguro et al., 2007) after obtaining written permission
from its proprietor (Paul Jones, University of London, London,
UK, on August 28. 2012).
Pulmonary Function Testing
Lung function was assessed using whole-body plethysmography,
conducted in compliance with the ATS/ERS criteria (Stocks et al.,
2001; Miller et al., 2005; Wanger et al., 2005) (Piston whole-body
plethysmograph PDT-111/p, Piston Medical, Hungary, equipped
with automatic BTPS correction for cabin temperature, humidity
and pressure as well as full automatic calibration and leakage
test). Patients were asked to take their medication as usual on the
morning of their examination (thus plethysmography was done
with patients being on asthma control therapy). Best of three
technically sound maneuvers was analyzed for each participant.
At least two separate and technically appropriate measurements
were conducted for resistance curves (eachmeasurement consists
recordings of at least 5 resistance loops) and results were
accepted only if they were the same for both measurements.
Raw pulmonary function data and percent predicted of normal
reference values were recorded using algorithms provided by the
manufacturer. The following parameters were included in the
statistical analysis: Raw, FEV1% pred, FVC% pred, FEV1/FVC%
pred, FEF25-75% % pred, RV% pred, TLC% pred, RV/TLC%
pred.
Blood Samples
Routine laboratory investigations were performed on the
morning of the study after an overnight fast, according to
the standard operational procedures of the Department of
Laboratory Medicine (University of Debrecen) as described
previously (Papp et al., 2017). Briefly, serum or plasma samples
were used to determine parameters descriptive of carbohydrate
and lipid homeostasis, of kidney, liver, and muscle function, and
of inflammation. CRP was dichotomized as high vs. normal using
the cutoff of 4.6 and 5.2 mg/L for female and male patients,
respectively. HOMA index was computed as previously (Zsuga
et al., 2007). Serum samples for the determination of irisin and
BDNF were frozen within 60min and stored at −80◦C until
further analysis.
Determination of Serum Irisin and BDNF
Serum irisin levels were determined with a commercially
available ELISA kit (Phoenix Pharmaceuticals, Burlingame,
CA, USA), compliant of the manufacturer’s instructions.
Summarizing, 50 µl of standard or sample (diluted 2 times), 25
µl primary antibody, and 25 µl biotinylated peptide were added
to each well and were incubated at room temperature for 2 h.
Next, the plates were washed four times and 100 µl/well SA-
HRP solution was added for an hour-long incubation at room
temperature. After washing, 100µl/well of substrate solution was
added and incubated for another 1 h, following which 100µl/well
of 2N HCl was used to terminate the reaction. Absorbance was
read immediately at 450 nm. The irisin standard curve was linear
from 1.34 to 29.0 ng/ml, and the detection limit was 1.34 ng/ml, in
accordance with the information provided by the manufacturer.
Similarly, serum BDNF levels were measured in agreement
with the manufacturer’s instructions (Sigma-Aldrich, MO,
USA). Briefly, standards and samples (diluted 100-fold) were
administered into 96-well microplates coated with anti-BDNF
monoclonal antibody and incubated at 4◦C overnight. After this
step, the plates were washed 4 times, and 100 µl biotinylated
anti-human BDNF Detector Antibody was added to each well.
Plates were incubated with gentle shaking for 1 h. Next, the wells
were washed and 100 µl HRP-Streptavidin solution was added
to each well that was followed by a 45-min long incubation
period at room temperature with gentle shaking. Samples were
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washed again, then to induce a color reaction 100 µl TMB One-
Step Substrate Reagent was added to each well and incubation
continued for 30min. The reaction was stopped using the stop
solution supplied by themanufacturer. The absorbance at 450 nm
wasmeasured immediately with an automatedmicroplate reader.
The detection limit for BDNF was <80 pg/ml.
A standard curve showing linear relationship between optical
density and concentration of irisin as well as BDNFwere obtained
with each plate. All measurements were performed in duplicate.
St. George’s Respiratory Questionnaire
(SGRQ)
The Hungarian version of SGRQ validated for a 1-month
recall period was delivered using supervised self-administration,
according to the SGRQ manual supplied by the copyright holder
(Jones et al., 1991) and as described previously (Papp et al., 2017).
SGRQ yields a Total score descriptive of the overall influence
of the disease in terms of health status and three component
scores, the Symptoms, the Activity, and the Impacts score. The
main outcome measure of interest was the SGRQ Impacts score,
as it characterizes disturbances of the psycho-social functioning,
and thereby shows strong correlation with distress disorder
(Jones et al., 1991). Scores are expressed as a percentage, with
100% representing the worst and 0% indicating the best possible
subjective health status. Differences in scores were considered
clinically meaningful if they exceeded 4 percent points (Jones,
2005). Data entry was performed by two independent raters
using a proprietor-supplied SGRQ calculator (Ferrer et al.,
2002). Raters were blinded to patients’ irisin and BDNF levels.
Inter-rater variability assessed by Spearman correlation provided
coefficients of 0.976 (p < 0.001), 0.997 (p < 0.001), 0.998 (p <
0.001), and 0.998 (p< 0.001) for the Symptoms, Activity, Impacts
and Total scores, respectively (Impacts score was unavailable for
one patient). The mean of scores obtained by the independent
raters was used for statistical analysis.
Statistical Analysis
Normality for continuous variables was checked with Shapiro–
Wilk test. If distribution was Gaussian, Student’s t-test was used
for the comparison of two data sets (and data were presented as
mean ± SD), if not, Mann–Whitney U-test was performed (and
data were presented as median; interquartile range). Frequencies
were compared with Pearson’s χ2 test.
Descriptive statistics were provided for the whole data set
and the data dichotomized according to the median of two
parameters, the Impacts score (as cutoff value). Patients with
Impacts score <22.53% and ≥22.53% were categorized into the
lower (n = 84) and higher Impacts score group (n = 83),
corresponding to the presence of less (or no) and more severe
distress disorder, respectively.
The correlation between the Impacts score and (transformed)
serum irisin level was establishedwith Pearson’s correlation in the
whole data set as well as in the lower and higher BDNF groups.
Serum irisin values underwent a reciprocal transformation to
ensure Gaussian distribution.
In order to account for potential confounders, multiple
regression modeling was carried out. This procedure was
initiated by assessing normality of each variable. Values of HgA1c,
HOMA index, CK, HDL-cholesterol, triglyceride, sTSH, and
Raw were log-transformed, furthermore reciprocal of urea and
reciprocal of square of glucose concentration were computed
to get hold of the Gaussian distribution of variables. Simple
linear regression analysis was performed to identify possible
determinants of the Impacts score (characteristic of distress
disorder) as well as the (reciprocal of) serum irisin. The influence
of traditional confounding factors (age, gender, height) as well
as disease duration were assessed. Missing data were omitted.
Simple linear regression revealed interaction between height and
weight squared. After the simple regression, age, gender, height
(in interaction with weight squared) (as a priori variables) as well
as all significant regressors were introduced into a multiple linear
regression model to further quantify the relationship between
the Impacts score and serum irisin concentration. Other SGRQ
scores were omitted due to their high collinearity with the
Impacts score. Lung function parameters yielding significant
regressors were combined into a single parameter descriptive
of lung function using principal component analysis. Variables
were entered in the model simultaneously, and then factors not
significantly contributing to the model were deleted. (Eventually,
the final model contained all variables identified a priori, the
composite of lung function parameters and the history of
dyslipidemia.) In addition, the final model was stratified with
respect to the median of BDNF. Patients with BDNF level
<311.4 µmol/L and ≥311.4 µmol/L were categorized into the
lower (n = 84) and higher BDNF group (n = 83), respectively.
Heteroskedasticity and goodness of fit for the model was assessed
by Cook-Weisberg and Ramsey tests, respectively.
Statistical analysis was performed with Stata 13.0 software
(Stata Corporation). Values are given as mean ± SD or medians
(with interquartile ranges: IQR), excepting regression coefficients
which are presented with their 95% confidence intervals (CI).
RESULTS
Patients
The basic characteristics of our asthma patient cohort (n = 167)
were previously described (Tajti et al., accepted). The median
irisin level (IQR) was 7.87 (7.15–8.82) ng/mL in the whole
sample, and it was 8.03 (7.14–9.50) ng/mL, and 7.86 (7.15–8.73)
ng/mL, among male and female patients, respectively. The mean
of serum± BDNF level was 314.46± 118.68 ng/mL in the whole
sample and it was 300.07 ± 107.58 and 326.48 ± 126.55 ng/mL
among men and women, respectively. No statistical difference
was present in either serum irisin or serum BDNF levels with
respect to gender. The main demographic, anthropometric and
anamnestic data, pulmonary function, laboratory and SGRQ
parameters are summarized in Table 1.
Comparison of Patients Regarding
Distress Disorder
The two strata of our asthma cohort, dichotomized based on
the median of Impacts score (reflective of the severity of distress
disorder present), were homogenous regarding most parameters
investigated (Table 2). Nonetheless, patients with more severe
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TABLE 1 | The main characteristics of the asthma cohort (n = 167).
Parameters
Age (years) 48 (36–58)
Gender (f/m) 91/76
Smoker (n/y) 145/22
Smoking (years) 0 (0–1)
Smoking (pack-years) 0 (0–3.375)
Diabetes (n/y) 159/8
Dyslipidemia (n/y) 118/49
RR systolic (mmHg) 131.56 ± 15.24
RR diastolic (mmHg) 84.31 ± 10.68
Hypertension (n/y) 104/63
Disease duration (years) 15 (10–20)
Waist (cm) 96.37 ± 13.07
Weight (kg) 75 (65–88)
Height (m) 1.68 ± 0.10
Irisin (ng/mL) 7.87 (7.15–8.82)
BDNF (ng/mL) 314.46 ± 118.68
Urea (mmol/L) 4.4 (3.9–5.5)
Creatinine (µmol/L) 69 (58–79)
GFR (ml/min/1.73 m2) 91 (85–91)
GOT (U/L) 19.5 (16–25)
GPT (U/L) 19 (14–29)
γGT (U/L) 22 (16–33)
CK (U/L) 111.5 (81–160)
LDH (U/L) 196 (180–224)
Glucose (mmol/L) 5 (4.3–5.4)
Insulin (mU/L) 9.1 (6.3–17)
HgA1C (%) 5.4 (5–5.8)
HOMA 2.00 (1.30–4.13)
Cholesterol (mmol/L) 5.30 ± 1.18
LDL-C (mmol/L) 3.16 ± 0.93
HDL-C (mmol/L) 1.4 (1.2–1.8)
Apo-A1 (g/L) 1.59 ± 0.29
ApoB (g/L) 0.99 (0.85–1.18)
Lp(a) (mg/L) 122.5 (52–376)
TG (mmol/L) 1.3 (0.9–2)
CRP (high/low) 30/136
Fibrinogen (g/L) 3.33 ± 0.64
Procalcitonin (µg/L) 0 (0–0)
Steroid use (n/y) 11/156
SGRQ symptoms score 28.65 (11.70–51.75)
SGRQ impacts score 22.53 (8.93–38.44)
SGRQ activity score 47.24 (23.61–59.45)
SGRQ total score 32.16 (17.10–47.11)
Data are presented as mean± SD or median (interquartile range) unless otherwise stated.
f/m, female/male; y/n, yes/no; SGRQ, St. George’s Respiratory Questionnaire.
form of distress disorder (i.e., those in the higher Impacts
score group) were significantly older, shorter, had smoked more
(reflected by pack-years), and had higher serum triglyceride and
fibrinogen but lower irisin levels. In addition, they performed
poorer in the lung function test reflected by worse parameters
in terms of FVC% pred, FEV1% pred, FEF25-75% pred %, RV%
TABLE 2 | Main characteristics of two groups of the asthma cohort dichotomized
according to the severity of distress disorder indicated by the SGRQ’s Impacts
score.
Parameters Lower impacts
score
Higher impacts score p
Age (years) 40.5 (28.5–59.5) 52 (43–57) 0.003
Smoking (pack-years) 0 (0–0.5) 0 (0–5) 0.03
Dyslipidemia present (n/y) 67/17 51/32 0.009
Hypertension present (n/y) 62/22 42/41 0.002
Height (m) 1.70 ± 0.10 1.66 ± 0.10 0.003
Irisin (ng/mL) 8.187 (7.402–9.312) 7.666 (6.838–8.54) 0.02
Triglyceride (mmol/L) 1.2 (0.9–1.8) 1.6 (1–2) 0.04
Fibrinogen (g/L) 3.18 ± 0.62 3.49 ± 0.62 0.001
FVC % pred 95.33 ± 13.59 90.05 ± 13.58 0.02
FEV1 % pred 90.27 ± 13.86 82.33 ± 15.20 <0.001
FEF25-75 % pred 72.56 ± 22.06 61.11 ± 21.05 0.001
RV % pred 129 (112–146) 139 (124−169) 0.01
RV/TLC % pred 117.60 ± 19.11 129.46 ± 19.32 <0.001
Raw current 0.2 (0.17–0.25) 0.24 (0.19–0.32) 0.003
Symptom score 15.43 (8.40–26.87) 50.46 (31.44–66.22) <0.001
Activity score 29.38 (11.56–42.82) 59.45 (47.68–66.95) <0.001
Total score 17.10 (9.22–25.57) 47.11 (37.88–56.10) <0.001
The lower (n = 84) and higher (n = 83) Impacts score group had Impacts score
<22.53 or ≥22.53, respectively. Only parameters with significant difference are indicated.
Comparison of smoking ( in years), presence or absence of diabetes, myocardial infarct,
stroke, and steroid use in case history, RR systolic (mmHg), RR diastolic (mmHg),
disease duration (years), waist (cm), weight (kg), BDNF (ng/mL), urea (mmol/L), creatinine
(µmol/L), GFR (mL/min/1.73 m2), GOT (U/L), GPT (U/L), γGT (U/L), CK (U/L), LDH (U/L),
glucose (mmol/L), insulin (mU/L), HgA1c (%), HOMA index, cholesterol (mmol/L), LDL-C
(mmol/L), HDL-C (mmol/L), CRP (mg/L), CRP kat (low/high), procalcitonin (µg/L), sTSH
(mU/L) showed no significant difference between the two groups. Data are presented as
mean ± SD or median (interquartile range), unless otherwise stated. Differences between
the two groups were considered significant at p < 0.05, clinically significant difference
between component scores are indicated in bold.
pred, RV/TLC% pred, and Raw, and had significantly higher
Symptoms, Activity and (as a consequence) Total scores. The
difference of scores was clinically meaningful, e.g., it was higher
than 4 points (Jones, 2005). Furthermore, higher proportion
of patients in the higher Impacts score group suffered from
hypertension and dyslipidemia (Table 2).
Associations between SGRQ’s Impacts
Score, Serum Irisin, and BDNF Levels
The Impacts score and reciprocal of serum irisin level showed
significant positive correlation in the whole patient cohort
(Pearson correlation coefficient: 0.19, p = 0.014; Figure 1). The
correlation coefficient increased indicating stronger correlation
(and, despite the smaller patient number, remained statistically
significant) in the stratum with higher BDNF levels, while it
decreased (and lost its statistical significance) in the lower BDNF
group (Pearson correlation coefficient: 0.25 and 0.11, p = 0.025
and p= 0.30, respectively). This suggests that serum irisin level is
associated with processes that lead to disease-related impairment
of psycho-social function among asthma patients, an effect that
is more pronounced if higher serum irisin concentration is
accompanied with higher serum BDNF level.
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FIGURE 1 | Correlation of the Impacts score of SGRQ and reciprocal of serum irisin concentration in the whole data set (n = 167). The gray zone indicates the 95%
confidence interval, while the blue line (in it) shows the fitted values of the reciprocal of irisin and Impacts score data pairs.
Simple linear regression yielded corroborating results upon
evaluating the relationship between Impacts score and reciprocal
of irisin (Table 3). This relationship remained significant after
adjusting for all significant predictors and a priori determinants
by means of multiple linear regression. The Impacts score
and reciprocal of irisin showed a strong, significant, positive
association (β: 147.74; CI: 42.17, 253.30; p = 0.006), which
was even more pronounced (e.g., the regression coefficient was
higher) in the higher BDNF group (β: 213.38; CI: 56.38, 370.38;
p = 0.008), while it was weaker (an effect reflected by lower
regression coefficient and lack of statistical significance) in the
lower BDNF group (β: 60.89; CI: −108.55, 230.33; p = 0.48).
All models (the full model as well as the stratified ones) were
significant (p< 0.001, p= 0.040, p= 0.003). The Cook-Weisberg
test showed no heteroskedasticity for the full model and strata
with higher and lower BDNF levels (p = 0.55, p = 0.22, and p
= 0.79, respectively). Moreover, all three models showed good fit
reflected by the locally weighted scatterplot smoothing (Figure 2)
as well as by the Ramsey test (p = 0.51, p = 0.28, and p = 0.55
for the whole data set and strata with higher and lower BDNF
concentrations, respectively).
The final multiple linear regression model (built for the
Impacts score) contained only dyslipidemia in addition to
the reciprocal of irisin and a priori identified parameters.
The presence of dyslipidemia showed a significant, positive
association with the Impacts score of asthma patients (β: 7.01; CI:
0.85, 13.35; p = 0.026), a relationship that was only significant in
the whole data set.
DISCUSSION
Our major finding is that severity of distress disorder
(characterized by the Impacts score of SGRQ) showed robust
positive linear relationship with the reciprocal of serum irisin
among adult asthma patients, undertaking asthma controller
therapy (including, for most patients, an inhaled corticosteroid).
Interestingly, severity of distress disorder was more closely
associated with the (reciprocal of) serum irisin concentration
in the patient stratum with higher BDNF levels, while this
association became statistically non-significant in the stratum
with lower BDNF levels. The linear relationship remained
significant following adjustment for a priori variables and
potential confounders by means of multiple linear regression. In
addition, the final model identified the presence of dyslipidemia
as a significant regressor influencing the Impacts score.
Quantification of serum irisin levels in asthma for the first time
may also be considered as a merit of the study.
Our main finding, that the positive linear relationship
between the Impacts score reflective of distress disorder and the
(reciprocal of) serum irisin varies with respect to the BDNF
level, implicates the possibility of an interaction between these
two factors in the context of distress disorder. This finding
corroborates our previous hypothesis that serum irisin, via
BDNF, may influence reinforcement learning and allied processes
including contextual learning (Zsuga et al., 2016c). Furthermore,
it is in agreement with our previous report, which have also
shown the alteration of irisin/BDNF axis in connection with
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TABLE 3 | Significant predictors of the SGRQ’s Impacts score and the reciprocal
of serum irisin levels determined using simple linear regression for the whole data
set (n = 165; data of two patients were not complete).
Parameter Coefficient (95% CI) p
SIMPLE LINEAR REGRESSION OF IMPACTS SCORE
Age 0.30 (0.122, 0.49) 0.001
Inverse of irisin 138.54 (28.47, 248.61) 0.014
Height −50.58 (−78.01, −23.15) <0.01
Albumin −1.43 (−2.40, −0.47) 0.004
Log CK −6.27 (−11.72, −0.83) 0.024
Log TG 5.10 (0.08, 10.12) 0.046
Fibrinogen 5.41 (1.07, 9.75) 0.015
FVC % pred −0.31 (−0.52, −0.11) 0.003
FEV1% pred −0.33 (−0.52, −0.15) 0.001
FEF25-75% % pred −0.18 (−0.31, −0.05) 0.005
RV % pred 0.09 (0.0002, 0.17) 0.049
RV/TLC % pred 0.28 (0.14, 0.42) <0.001
Log Raw 8.98 (1.91, 16.05) 0.013
Symptoms score 0.52 (0.44, 0.61) <0.001
Activity score 0.56 (0.47, 0.65) <0.001
Total score 0.94 (0.90, 0.99) <0.001
Dyslipidemia present 9.72 (3.75, 15.70) 0.002
Hypertension present 8.36 (2.71, 14.00) 0.004
Atherosclerosis present 13.32 (2.20, 24.44) 0.019
Obesity present 8.20 (2.47, 13.93) 0.005
Steroid use 11.23 (0.06, 22.41) 0.049
GFR 6.39 (0.55, 12.24) 0.032
SIMPLE LINEAR REGRESSION OF RECIPROCAL OF IRISIN
Lp(a) 1.39·10−5 (1.89·10−6, 2.59·10−5) 0.024
Impacts score 2.6·10−4 (5.35·10−5, 4.67·10−4) 0.014
Total score 2.17·10−4 (1.04·10−5, 4.24·10−4) 0.040
Myocardial infarct present 0.03 (0.009, 0.057) 0.008
Steroid use 0.02 (0.002, 0.032) 0.029
Regression coefficient values are presented with their 95% confidence limits.
mood disturbances among COPD patients (Papp et al., 2017).
Based on the original report of Wrann et al. (2013) reporting
that both FNDC5/irisin is able to induce the expression of
BDNF in the hippocampus, several reviews discuss the probable
involvement of FNDC5/irisin/BDNF axis in brain health (Chen
et al., 2016; Ryan and Nolan, 2016; Camandola and Mattson,
2017; Satoh et al., 2017). Nonetheless, clinical reports also show
some inconclusive findings with respect to the relationship
between BDNF and irisin levels. For example, in a small
clinical sample comprising of endurance athletes and sedentary
controls, irisin and BDNF levels as well as metrics for cognitive
performance were higher in the athletes’ group (Belviranli
et al., 2016). Yet in a different study, 3-month long CrossFit
training was shown to increase aerobic capacity and BDNF
levels but not irisin levels in a group of young physically active
volunteers (Murawska-Cialowicz et al., 2015). Nevertheless, the
controversies regarding the role irisin may assume in neuronal
health and need for further clinical research were also articulated
previously (Farshbaf et al., 2016).
Generalized anxiety disorder and major depressive disorder
are considered as distinct entities according to nosological
systems, classification schemes which have been criticized
for being agnostic for underlying etiological factors (Renna
et al., 2017). Nevertheless, acknowledging the high co-
morbidity for anxiety and depressive disorders, the new
Diagnostic and Statistical Manual of Mental Disorders (DSM-
V) defines a combined anxiety and depression category
(Wegner et al., 2014). Convergence of previously distinct
entities in such phenomenological nosological systems is well
aligned with the need of identifying common neurobiological
pathways involved in the etiopathogenesis of distress disorder
(Renna et al., 2017). Linking these psychiatric disorders
to the theoretical framework of the proactive model of
reinforcement learning acknowledges the possibility that these
disorders may evolve due to the disruption of the same core
system.
Reinforcement learning is a central process that guides
individual behavior in a way that immediate and cumulated
future rewards are maximized in the long term (Maia, 2009). The
brain has two fundamentally different, but closely interconnected
systems governing model-based and model-free reinforcement
learning, paradigms that differ in terms of use of a world
model. Model-based reinforcement utilizes contextual learning
to build a world model by the function of the hippocampus,
amygdala and medial orbitofrontal cortex (mOFC) (Zsuga et al.,
2016a,b). On the other hand, model-free reinforcement learning
samples the environment to obtain current information and
compares it to cached values to emit the canonical reward
prediction error signal, the function of dopaminerg neurons
emanating from the ventral tegmental area (VTA) (Schultz
et al., 1997; Schultz, 2007). The mutual influence of these
systems has been implicated previously as the dopaminergic
reward prediction error signal may contribute to updating
the reward attribute of the context frames (by means of
VTA’s dopaminergic input on the hippocampus, amygdala and
mOFC), furthermore glutaminergic outflow of mOFCmodulates
the function of model-free structures including VTA (Zsuga
et al., 2016a,b). Importantly, alteration of several attributes
of reinforcement learning (e.g., learning rate, primary reward
sensitivity) has been described in relation with both anxiety and
depression (Huys et al., 2013; Treadway et al., 2013; Pulcu et al.,
2014).
Irisin and its downstreammediator BDNF are humoral factors
that target several structures (e.g., hippocampus, amygdala, VTA)
and, accordingly, may modulate reinforcement learning (Zsuga
et al., 2016c). Irisin, either of peripheral or neuronal origin
(Wrann et al., 2013), has the ability to trigger the expression
of BDNF in these structures (Wrann et al., 2013; Camandola
and Mattson, 2017). The exact molecular mechanism is yet
to be identified (Xu, 2013; Camandola and Mattson, 2017).
BDNF regulates dopamine 3 (D3) signaling pathways in VTA
(Guillin et al., 2003; Collo et al., 2014), a pathway that has
fundamental influence on dopamine’s effect with respect to
structural plasticity in the model-free reinforcement learning
system (Schultz, 2007). Furthermore, high expression of BDNF
parallels enhancement of long-term potentiation underlying
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FIGURE 2 | The final multiple linear regression model characterizing the relationship between Impacts score of SGRQ and reciprocal of serum irisin concentration in
the whole data set (n = 165; data of two patients were not complete). The blue dots indicate the raw (i.e., original) data, while the red dots indicate the fitted values
obtained by multiple linear regression. The green and orange lines indicate the fitted curves for raw data and for data provided by multiple regression. The fitted curves
were obtained by locally weighted scatterplot smoothing (lowess).
synaptic plasticity, neurogenesis, and neuronal differentiation
in the model-based system’s amygdala, hippocampus, and
prefrontal cortex (Chen et al., 2016; Camandola and Mattson,
2017). Summarizing, the irisin/BDNF axis modulates several
structures constituting the neurobiological system underlying
reinforcement learning.
The role of BDNF in distress disorder is established to the
extent that BDNF is emerging as a biomarker (Polyakova et al.,
2015; Ihara et al., 2016). Decreased BDNF levels were shown to
parallel progression of depression, inhibit neurogenesis, while
causing structural and functional changes in the hippocampus
(Jeon and Kim, 2016). Conversely, antidepressant therapy was
shown to increase BDNF levels and promoted the recovery
of hippocampal nerve cells and improved plasticity (Groves,
2007; Jeon and Kim, 2016). Accumulating evidence led to
the formalization of the neurotrophic theory of depression
(Duman and Monteggia, 2006; Bus et al., 2015). For example,
a systematic review and meta-analysis of 20 studies including
1,054 patients provided robust support for the theory as the
authors concluded that BDNF concentration correlated with
depression score changes, and improvement of depression
due to antidepressant therapy is associated with neuroplastic
changes and increased BDNF levels (Brunoni et al., 2008).
The presence of longitudinal association between serum BDNF
and depression further supports BDNF’s significance. Bus
et al reported that baseline BDNF levels showed a substantial
decline in previously depressed and remitted patients at a
2 years’ follow-up (Bus et al., 2015). Complexity of BDNF’s
influence is getting more and more acknowledged since the
contrasting consequences of changes in neuronal plasticity
emerge dependent on the involvement of distinct pathways
(e.g., hippocampal or VTA/ventral striatal ones; Groves, 2007).
Preclinical models showed that increasing influence of BDNF
in VTA and ventral striatum may induce depression (Jeon and
Kim, 2016). Thus, it was previously suggested that BDNF may
act as a critical modulator of the activity-dependent plasticity
of distinct neural networks (Allen and Dawbarn, 2006; Farshbaf
et al., 2016).
In our previous work, we investigated the possible
involvement of the irisin/BDNF axis in the evolution of
distress disorder (also quantified by the Impacts component
score of SGRQ) in a COPD patient cohort (Papp et al., 2017).
Although, similarly to our current findings in asthma, a
significant linear relationship was present between the Impacts
score and reciprocal of serum irisin levels among COPD patients
(β: 419.97; CI: 204.31, 635.63; p< 0.001), the interaction between
serum irisin and BDNF levels was found to be different. In the
case of COPD patients, the linear association became stronger
in the stratum of patients with BDNF levels in the lower half
(β: 434.11; 95% CI: 166.17, 702.05; p = 0.002; Papp et al., 2017).
On contrary, results in our cohort of asthma patients in the
present study showed more robust linear association in the
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stratum comprising patients in the upper half of the BDNF
levels.
Several causes may underlie this difference. On one hand,
the different role of BDNF in the etiopathogenesis of these
two similar, but distinct disease entities must be acknowledged.
The ability of BDNF to induce airflow limitation and to
promote airway hyperresponsiveness to histamine has been
described in animal models of asthma as well as in asthma
patients (Lommatzsch et al., 2005a, 2009; Prakash and Martin,
2014). Increased neuronal activity and sensitivity underlying
these symptoms have been linked to upregulation of BDNF
(Lommatzsch et al., 2003; Braun et al., 2004). Meanwhile in
COPD, BDNF’s role in airway pathology was only implicated
in the context of airway remodeling (Pera et al., 2014). On the
other hand, the fact that both patient populations were treated
as clinically warranted may also carry distinct implications. In
the management of asthma inhaled corticosteroid therapy is
the preferred controller choice from step 1 and β2 agonists
are considered only as reliever therapy in steps 1 and 2 and
are introduced as controllers from step 3 (Global Initiative
for Asthma, 2016). On the other hand, β2 agonists are the
first choice of therapy from the early stages of stable COPD
(e.g., GOLD 1 and GOLD 2 stage) with corticosteroid use
being indicated from the more advanced (GOLD 3 and
GOLD 4) severity stages (Vogelmeier et al., 2017). Prior
clinical reports have shown the ability of β2 agonists to
increase BDNF concentration in platelets and (consequently)
serum, parallel to the deterioration of airway responsiveness
(Lommatzsch et al., 2009). Moreover, the causative effect of
BDNF in the paradoxical loss of asthma control following
unbalanced use of β2 agonists has been proposed (Hogg et al.,
2004; Nelson et al., 2006). This deleterious effect may be
counterbalanced by co-administration of inhaled corticosteroids
(Lommatzsch et al., 2009). Based on these considerations,
differential alteration of BDNF-related mechanisms in these
two diseases seems plausible, although further investigations are
needed.
Limited number of reports are available concerning the
change of serum BDNF levels in asthma. While the serum
BDNF levels reported in the current investigation exceed that
of Virchow’s group investigating asthma patients (Lommatzsch
et al., 2005a,b), they are within the range measured in
other studies involving healthy individuals and other patient
populations, with reported serum BDNF levels spanning
over four orders of magnitude (!), ranging from 0.005 to
280 ng/ml using different ELISA kits (Failla et al., 2016;
Ihara et al., 2016; Jacoby et al., 2016; Kheirouri et al.,
2016). At the same time, to the best of our knowledge,
no previous report is available regarding the serum irisin
concentrations in asthma patients. Nevertheless, investigations
dealing with other populations showed comparable irisin levels:
26.3 (IQR: 22.6, 32.4) ng/ml, 53.7 (IQR: 46.7, 62.8) ng/ml,
58.5 (42.8, 78.9) ng/ml in smokers with and without COPD,
and in non-smoking individuals, respectively (Kureya et al.,
2016).
In the current study, based on the final multiple regression
model, we have found that dyslipidemia is a significant
determinant of the Impacts score, indicating that disruption of
lipid metabolism may worsen the severity of distress disorder
in asthma. The possible contribution of dyslipidemia to the
pathogenesis of asthma has been suggested previously. For
example, dyslipidemia is known to be associated with increased
asthma prevalence, moreover, based on results from preclinical
(Gowdy and Fessler, 2013) and clinical (Fenger et al., 2013)
studies, it has been implicated as a risk factor for asthma.
Corroborating findings were also reported by Rastogi et al. who
found that dyslipidemia is a predictor of pulmonary function
deficits (Rastogi et al., 2015).
A limitation of the present study is that severity of distress
disease was quantified by the Impacts score of SGRQ given that
exact identification of anxiety or mood disorders according to
DSM-V would have caused extra inconvenience for the asthma
outpatients and might have been difficult due to the great
overlap between symptoms that may be secondary to the mental
disorders or asthma per se (Porsbjerg and Menzies-Gow, 2017).
Nonetheless, the robust correlation between depression and
Impacts score has been previously acknowledged (Jones et al.,
1992), giving way to the proposition that irisin may serve as a
link between altered irisin/BDNF path and evolution of distress
disorder.
The lack of post-bronchodilator whole-body
plethysmography may also be viewed as a limitation. However,
our patient population received asthma control therapy for 15
(IQR: 10–20) years, and patients were instructed to take their
medication as usual in the morning of their examinations. Thus,
our findings must be interpreted as on treatment results.
Finally, merits of the current work should be articulated
like the relatively large clinical sample, implementation of
specific instruments (whole-body plethysmography and SGRQ,
a validated disease-specific questionnaire), and stringent data
analysis.
CONCLUSIONS
The main finding of the present study is that alteration of
irisin/BDNF axis parallels the evolution of distress disorder
in asthma. To the best of our knowledge, the current study
is the first to assess the relationship among serum irisin
level, serum BDNF level and the occurrence (and severity)
of distress disorder in asthma. The strong positive association
between the reciprocal of serum irisin and Impacts score
(i.e., the inverse proportionality between serum irisin and
Impacts score) in the multiple linear regression model indicates
that circulating irisin is associated with a lower occurrence
and/or milder extent of distress disorder. Our further finding
that irisin’s effect is more pronounced if serum BDNF level
is higher adds clinical evidence to prior observations in
preclinical models regarding this pathway. Nevertheless precise
mechanisms should be elucidated in the future. Summarizing,
irisin may contribute to BDNF’s ability to influence mood
and anxiety by altering contextual learning in structures
under BDNF control thus induce the evolution of distress
disorder.
Frontiers in Neuroscience | www.frontiersin.org 9 November 2017 | Volume 11 | Article 653
Szilasi et al. Irisin and BDNF in Bronchial Asthma
AVAILABILITY OF DATA AND MATERIAL
Database underlying results of the present study is being
on further evaluation, thus it is not freely available
yet.
AUTHOR CONTRIBUTIONS
KP, AM, AF, CP, and MES: participated in the patient
recruitment and collection of clinical data; LK: helped to
perform the statistical analysis; VV and IS: carried out the
irisin and BDNF measurement; GT and RG: participated in the
design of the study and helped to draft the manuscript; MS:
coordinated the patient recruitment and clinical data collection;
JZ: conceived of the study, performed the statistical analysis and
completed the manuscript; All authors read and approved the
final manuscript.
FUNDING
Our current research was supported by the Scientific Research
Grant of the Hungarian Foundation for Pulmonology (awarded
in 2015) and the Hungarian Brain Research Program
(KTIA_13_NAP-A-V/2). The role of the funding body was
to provide funding based on a predefined research proposal.
ACKNOWLEDGMENTS
The authors thank the technical contribution of Anett Lepp to
this study.
REFERENCES
Allen, S. J., and Dawbarn, D. (2006). Clinical relevance of the neurotrophins and
their receptors. Clin. Sci. 110, 175–191. doi: 10.1042/CS20050161
Bar, M. (2007). The proactive brain: using analogies and associations to generate
predictions. Trends Cogn. Sci. 11, 280–289. doi: 10.1016/j.tics.2007.05.005
Bar, M. (2009). A cognitive neuroscience hypothesis of mood and depression.
Trends Cogn. Sci. 13, 456–463. doi: 10.1016/j.tics.2009.08.009
Belviranli, M., Okudan, N., Kabak, B., Erdogan, M., and Karanfilci, M.
(2016). The relationship between brain-derived neurotrophic factor, irisin
and cognitive skills of endurance athletes. Phys. Sportsmed. 44, 290–296.
doi: 10.1080/00913847.2016.1196125
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., et al. (2012).
A PGC1-[agr]-dependent myokine that drives brown-fat-like development
of white fat and thermogenesis. Nature 481, 463–468. doi: 10.1038/nature
10777
Boulet, L. P., FitzGerald, J. M., Levy, M. L., Cruz, A. A., Pedersen, S., Haahtela,
T., et al. (2012). A guide to the translation of the Global Initiative for
Asthma (GINA) strategy into improved care. Eur. Respir. J. 39, 1220–1229.
doi: 10.1183/09031936.00184511
Braun, A., Lommatzsch, M., Neuhaus-Steinmetz, U., Quarcoo, D., Glaab, T.,
McGregor, G. P., et al. (2004). Brain-derived neurotrophic factor (BDNF)
contributes to neuronal dysfunction in amodel of allergic airway inflammation.
Br. J. Pharmacol. 141, 431–440. doi: 10.1038/sj.bjp.0705638
Brunner, W. M., Schreiner, P. J., Sood, A., and Jacobs, D. R. Jr. (2014). Depression
and risk of incident asthma in adults. The CARDIA study. Am. J. Respir. Crit.
Care Med. 189, 1044–1051. doi: 10.1164/rccm.201307-1349OC
Brunoni, A. R., Lopes, M., and Fregni, F. (2008). A systematic review and meta-
analysis of clinical studies on major depression and BDNF levels: implications
for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol. 11,
1169–1180. doi: 10.1017/S1461145708009309
Bus, B. A., Molendijk, M. L., Tendolkar, I., Penninx, B., Prickaerts, J., Elzinga,
B., et al. (2015). Chronic depression is associated with a pronounced decrease
in serum brain-derived neurotrophic factor over time. Mol. Psychiatry 20,
602–608. doi: 10.1038/mp.2014.83
Cagni, F. C., Campêlo, C. L. D. C., Coimbra, D. G., Barbosa, M. R.,
Júnior, L. G. O., Neto, A. B. S., et al. (2017). Association of BDNF
Val66MET polymorphism with Parkinson’s disease and depression
and anxiety symptoms. J. Neuropsychiatry Clin. Neurosci. 29, 142–147.
doi: 10.1176/appi.neuropsych.16040062
Camandola, S., and Mattson, M. P. (2017). Brain metabolism in health, aging, and
neurodegeneration. EMBO J. 36, 1474–1492. doi: 10.15252/embj.201695810
Chao, M. V., Rajagopal, R., and Lee, F. S. (2006). Neurotrophin signalling in health
and disease. Clin. Sci. 110, 167–173. doi: 10.1042/CS20050163
Chen, N., Li, Q., Liu, J., and Jia, S. (2016). Irisin, an exercise-induced myokine as a
metabolic regulator: an updated narrative review. Diabetes Metab. Res. Rev. 32,
51–59. doi: 10.1002/dmrr.2660
Collo, G., Cavalleri, L., and Spano, P. (2014). Structural plasticity in mesencephalic
dopaminergic neurons produced by drugs of abuse: critical role of BDNF and
dopamine. Front. Pharmacol. 5:259. doi: 10.3389/fphar.2014.00259
Duman, R. S., and Monteggia, L. M. (2006). A neurotrophic model
for stress-related mood disorders. Biol. Psychiatry 59, 1116–1127.
doi: 10.1016/j.biopsych.2006.02.013
Failla, M. D., Conley, Y. P., andWagner, A. K. (2016). Brain-Derived Neurotrophic
Factor (BDNF) in traumatic brain injury–related mortality: interrelationships
between genetics and acute systemic and central nervous system BDNF profiles.
Neurorehabil. Neural Repair 30, 83–93. doi: 10.1177/1545968315586465
Farshbaf, M. J., Ghaedi, K., Megraw, T. L., Curtiss, J., Faradonbeh, M. S., Vaziri,
P., et al. (2016). Does PGC1α/FNDC5/BDNF elicit the beneficial effects
of exercise on neurodegenerative disorders? Neuromolecular Med. 18, 1–15.
doi: 10.1007/s12017-015-8370-x
Fenger, R., Gonzalez-Quintela, A., Linneberg, A., Husemoen, L., Thuesen, B.,
Aadahl, M., et al. (2013). The relationship of serum triglycerides, serum HDL,
and obesity to the risk of wheezing in 85,555 adults. Respir. Med. 107, 816–824.
doi: 10.1016/j.rmed.2013.02.001
Ferrer, M., Villasante, C., Alonso, J., Sobradillo, V., Gabriel, R., Vilagut, G., et al.
(2002). Interpretation of quality of life scores from the St George’s Respiratory
Questionnaire. Eur. Respir. J. 19, 405–413. doi: 10.1183/09031936.02.00213202
Global Initiative for Asthma (2016). Global Strategy for Asthma, Management, and
Prevention. Global Initiative for Asthma. Available online at: www.ginasthma.
org
Goodwin, R. D. (2016). Toward improving our understanding of the link
between mental health, lung function, and asthma diagnosis. The challenge
of asthma measurement. Am. J. Respir. Crit. Care Med. 194, 1313–1315.
doi: 10.1164/rccm.201610-2016ED
Goodwin, R. D., Jacobi, F., and Thefeld, W. (2003). Mental disorders
and asthma in the community. Arch. Gen. Psychiatry 60, 1125–1130.
doi: 10.1001/archpsyc.60.11.1125
Gowdy, K. M., and Fessler, M. B. (2013). Emerging roles for cholesterol
and lipoproteins in lung disease. Pulm. Pharmacol. Ther. 26, 430–437.
doi: 10.1016/j.pupt.2012.06.002
Groves, J. (2007). Is it time to reassess the BDNF hypothesis of depression? Mol.
Psychiatry 12, 1079–1088. doi: 10.1038/sj.mp.4002075
Guillin, O., Griffon, N., Bezard, E., Leriche, L., Diaz, J., Gross, C., et al. (2003).
Brain-derived neurotrophic factor controls dopamine D3 receptor expression:
therapeutic implications in Parkinson’s disease. Eur. J. Pharmacol. 480, 89–95.
doi: 10.1016/j.ejphar.2003.08.096
Hogg, J. C., Chu, F., Utokaparch, S., Woods, R., Elliott, W. M., Buzatu,
L., et al. (2004). The nature of small-airway obstruction in chronic
obstructive pulmonary disease. N. Engl. J. Med. 350, 2645–2653.
doi: 10.1056/NEJMoa032158
Huys, Q. J., Pizzagalli, D. A., Bogdan, R., andDayan, P. (2013).Mapping anhedonia
onto reinforcement learning: a behavioural meta-analysis. Biol. Mood Anxiety
Disord. 3:12. doi: 10.1186/2045-5380-3-12
Frontiers in Neuroscience | www.frontiersin.org 10 November 2017 | Volume 11 | Article 653
Szilasi et al. Irisin and BDNF in Bronchial Asthma
Ihara, K., Yoshida, H., Jones, P. B., Hashizume, M., Suzuki, Y., Ishijima, H.,
et al. (2016). Serum BDNF levels before and after the development of mood
disorders: a case–control study in a population cohort. Transl. Psychiatry
6:e782. doi: 10.1038/tp.2016.47
Jacoby, A. S., Munkholm, K., Vinberg, M., Pedersen, B. K., and Kessing, L. V.
(2016). Cytokines, brain-derived neurotrophic factor and C-reactive protein
in bipolar I disorder–Results from a prospective study. J. Affect. Disord. 197,
167–174. doi: 10.1016/j.jad.2016.03.040
Jeon, S. W., and Kim, Y. (2016). Molecular neurobiology and promising new
treatment in depression. Int. J. Mol. Sci. 17:381. doi: 10.3390/ijms17030381
Jones, P. W. (2005). St. George’s respiratory questionnaire:MCID. COPD 2, 75–79.
doi: 10.1081/COPD-200050513
Jones, P. W., Quirk, F. H., and Baveystock, C. (1991). The St George’s respiratory
questionnaire. Respir. Med. 85, 25–31. doi: 10.1016/S0954-6111(06)80166-6
Jones, P. W., Quirk, F. H., Baveystock, C. M., and Littlejohns, P. (1992). A self-
complete measure of health status for chronic airflow limitation. Am. Rev.
Respir. Dis. 145, 1321–1327. doi: 10.1164/ajrccm/145.6.1321
Kheirouri, S., Noorazar, S. G., Alizadeh, M., and Dana-Alamdari, L. (2016).
Elevated brain-derived neurotrophic factor correlates negatively with severity
and duration of major depressive episodes. Cogn. Behav. Neurol. 29, 24–31.
doi: 10.1097/WNN.0000000000000089
Kureya, Y., Kanazawa, H., Ijiri, N., Tochino, Y.,Watanabe, T., Asai, K., et al. (2016).
Down-regulation of soluble α-Klotho is associated with reduction in serum
irisin levels in chronic obstructive pulmonary disease. Lung 194, 345–351.
doi: 10.1007/s00408-016-9870-7
Latsko, M. S., Gilman, T. L., Matt, L. M., Nylocks, K. M., Coifman, K. G., and
Jasnow, A. M. (2016). A novel interaction between Tryptophan Hydroxylase
2 (TPH2) gene polymorphism (rs4570625) and BDNF Val66Met predicts a
high-risk emotional phenotype in healthy subjects. PLoS ONE 11:e0162585.
doi: 10.1371/journal.pone.0162585
Levada, O. A., Cherednichenko, N. V., Trailin, A. V., and Troyan, A. S. (2016).
Plasma brain-derived neurotrophic factor as a biomarker for the main types of
mild neurocognitive disorders and treatment efficacy: a preliminary study. Dis.
Markers 2016:4095723. doi: 10.1155/2016/4095723
Loerbroks, A., Apfelbacher, C. J., Bosch, J. A., and Stürmer, T. (2010).
Depressive symptoms, social support, and risk of adult asthma in
a population-based cohort study. Psychosom. Med. 72, 309–315.
doi: 10.1097/PSY.0b013e3181d2f0f1
Lommatzsch, M., Braun, A., and Renz, H. (2003). Neurotrophins in
allergic airway dysfunction. Ann. N.Y. Acad. Sci. 992, 241–249.
doi: 10.1111/j.1749-6632.2003.tb03154.x
Lommatzsch, M., Lindner, Y., Edner, A., Bratke, K., Kuepper, M., and Virchow,
J. C. (2009). Adverse effects of salmeterol in asthma: a neuronal perspective.
Thorax 64, 763–769. doi: 10.1136/thx.2008.110916
Lommatzsch, M., Schloetcke, K., Klotz, J., Schuhbaeck, K., Zingler, D., Zingler,
C., et al. (2005a). Brain-derived neurotrophic factor in platelets and
airflow limitation in asthma. Am. J. Respir. Crit. Care Med. 171, 115–120.
doi: 10.1164/rccm.200406-758OC
Lommatzsch, M., Zingler, D., Schuhbaeck, K., Schloetcke, K., Zingler, C., Schuff-
Werner, P., et al. (2005b). The impact of age, weight and gender on
BDNF levels in human platelets and plasma. Neurobiol. Aging 26, 115–123.
doi: 10.1016/j.neurobiolaging.2004.03.002
Maia, T. V. (2009). Reinforcement learning, conditioning, and the brain:
successes and challenges. Cogn. Affect. Behav. Neurosci. 9, 343–364.
doi: 10.3758/CABN.9.4.343
Meguro, M., Barley, E. A., Spencer, S., and Jones, P. W. (2007). Development and
validation of an improved, COPD-specific version of the St. George Respiratory
Questionnaire. Chest 132, 456–463. doi: 10.1378/chest.06-0702
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates,
A., et al. (2005). Standardisation of spirometry. Eur. Respir. J. 26, 319–38.
doi: 10.1183/09031936.05.00034805
Murawska-Cialowicz, E.,Wojna, J., and Zuwala-Jagiello, J. (2015). Crossfit training
changes brain-derived neurotrophic factor and irisin levels at rest, after wingate
and progressive tests, and improves aerobic capacity and body composition of
young physically active men and women. J. Physiol. Pharmacol. 66, 811–821.
Available online at: http://www.jpp.krakow.pl/journal/archive/12_15/pdf/811_
12_15_article.pdf
Nascimento, C. M., Pereira, J. R., Pires de Andrade, L., Garuffi, M., Ayan, C.,
Kerr, D. S., et al. (2015). Physical exercise improves peripheral BDNF levels and
cognitive functions in mild cognitive impairment elderly with different BDNF
Val66Met genotypes. J. Alzheimer’s Dis. 43, 81–91. doi: 10.3233/JAD-140576
Nelson, H. S., Weiss, S. T., Bleecker, E. R., Yancey, S. W., and Dorinsky, P. M.
(2006). The Salmeterol Multicenter Asthma Research Trial: a comparison of
usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
Chest 129, 15–26. doi: 10.1378/chest.129.1.15
Opolski, M., and Wilson, I. (2005). Asthma and depression: a pragmatic review of
the literature and recommendations for future research. Clin. Pract. Epidemiol.
Ment. Health 1:18. doi: 10.1186/1745-0179-1-18
Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., and Kastin, A. J. (1998).
Transport of brain-derived neurotrophic factor across the blood–brain barrier.
Neuropharmacology 37, 1553–1561. doi: 10.1016/S0028-3908(98)00141-5
Papp, C., Pak, K., Erdei, T., Juhasz, B., Seres, I., Szentpéteri, A., et al. (2017).
Alteration of the irisin–brain-derived neurotrophic factor axis contributes to
disturbance of mood in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis.
12, 2023–2033. doi: 10.2147/COPD.S135701
Patten, S. B., Williams, J. V., Lavorato, D. H., Modgill, G., Jetté, N., and Eliasziw,
M. (2008). Major depression as a risk factor for chronic disease incidence:
longitudinal analyses in a general population cohort. Gen. Hosp. Psychiatry 30,
407–413. doi: 10.1016/j.genhosppsych.2008.05.001
Pera, T., Zuidhof, A. B., Smit, M., Menzen, M. H., Klein, T., Flik, G., et al. (2014).
Arginase inhibition prevents inflammation and remodeling in a guinea pig
model of chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 349,
229–238. doi: 10.1124/jpet.113.210138
Phillips, C., Baktir, M. A., Srivatsan, M., and Salehi, A. (2014). Neuroprotective
effects of physical activity on the brain: a closer look at trophic factor signaling.
Front. Cell. Neurosci. 8:170. doi: 10.3389/fncel.2014.00170
Polyakova, M., Stuke, K., Schuemberg, K., Mueller, K., Schoenknecht, P., and
Schroeter, M. L. (2015). BDNF as a biomarker for successful treatment of
mood disorders: a systematic & quantitative meta-analysis. J. Affect. Disord.
174, 432–440. doi: 10.1016/j.jad.2014.11.044
Porsbjerg, C., and Menzies-Gow, A. (2017). Co-morbidities in severe
asthma: clinical impact and management. Respirology 22, 651–661.
doi: 10.1111/resp.13026
Prakash, Y. S., and Martin, R. J. (2014). Brain-derived neurotrophic factor in the
airways. Pharmacol. Ther. 143, 74–86. doi: 10.1016/j.pharmthera.2014.02.006
Pulcu, E., Trotter, P., Thomas, E., McFarquhar, M., Juhász, G., Sahakian, B., et al.
(2014). Temporal discounting in major depressive disorder. Psychol. Med. 44,
1825–1834. doi: 10.1017/S0033291713002584
Rastogi, D., Fraser, S., Oh, J., Huber, A. M., Schulman, Y., Bhagtani, R. H.,
et al. (2015). Inflammation, metabolic dysregulation, and pulmonary function
among obese urban adolescents with asthma.Am. J. Respir. Crit. CareMed. 191,
149–160. doi: 10.1164/rccm.201409-1587OC
Renna, M. E., Quintero, J. M., Fresco, D. M., and Mennin, D. S. (2017). Emotion
regulation therapy: a mechanism-targeted treatment for disorders of distress.
Front. Psychol. 8:98. doi: 10.3389/fpsyg.2017.00098
Ryan, S. M., and Nolan, Y. M. (2016). Neuroinflammation negatively affects adult
hippocampal neurogenesis and cognition: can exercise compensate? Neurosci.
Biobehav. Rev. 61, 121–131. doi: 10.1016/j.neubiorev.2015.12.004
Satoh, A., Imai, S., and Guarente, L. (2017). The brain, sirtuins, and ageing. Nat.
Rev. Neurosci. 18, 362–374. doi: 10.1038/nrn.2017.42
Schultz, W. (2007). Behavioral dopamine signals. Trends Neurosci. 30, 203–210.
doi: 10.1016/j.tins.2007.03.007
Schultz, W., Dayan, P., and Montague, P. R. (1997). A neural
substrate of prediction and reward. Science 275, 1593–1599.
doi: 10.1126/science.275.5306.1593
Scott, K. M., Von Korff, M., Ormel, J., Zhang, M., Bruffaerts, R., Alonso,
J., et al. (2007). Mental disorders among adults with asthma: results from
the World Mental Health Survey. Gen. Hosp. Psychiatry 29, 123–133.
doi: 10.1016/j.genhosppsych.2006.12.006
Stocks, J., Godfrey, S., Beardsmore, C., Bar-Yishay, E., Castile, R., and ERS/AT
Task Force on Standards for Infant Respiratory Function Testing. European
Respiratory Society/American Thoracic Society (2001). Plethysmographic
measurements of lung volume and airway resistance. ERS/ATS Task
Force on Standards for Infant Respiratory Function Testing. European
Frontiers in Neuroscience | www.frontiersin.org 11 November 2017 | Volume 11 | Article 653
Szilasi et al. Irisin and BDNF in Bronchial Asthma
Respiratory Society/American Thoracic Society. Eur. Respir. J. 17, 302–312.
doi: 10.1183/09031936.01.17203020
Tajti, G., Papp, C., Kardos, L., Keki, S., Pak, K., Szilasi, M. E., et al.
(accepted). Positive correlation of airway resistance and serum asymmetric
dimethylarginine (ADMA) in bronchial asthma patients lacking evidence for
systemic inflammation. Allerg. Asthma Clin. Immunol.
Tamási, L., Balikó, Z., Bálint, B., Bártfai, Z., Bauknecht, É., Böszörményi Nagy,
G., et al. (2012). Az asztma diagnosztikájának, kezelésének és gondozásának
alapelvei felnottkorban. Med. Thoracalis 65, 307–328. Available online at:
https://lib.semmelweis.hu/sepub/pdf/2012/a567
Treadway, M. T., Buckholtz, J. W., and Zald, D. H. (2013). Perceived stress predicts
altered reward and loss feedback processing in medial prefrontal cortex. Front.
Hum. Neurosci. 7:180. doi: 10.3389/fnhum.2013.00180
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau,
J., et al. (2017). Global strategy for the diagnosis, management and prevention
of chronic obstructive lung disease 2017 report: GOLD Executive Summary.
Am. J. Respir. Crit. Care Med. 195, 557–582. doi: 10.1164/rccm.201701-0218PP
Von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C.,
Vandenbroucke, J. P., et al. (2007). The Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) statement:
guidelines for reporting observational studies. Prev. Med. 45, 247–251.
doi: 10.1016/j.ypmed.2007.08.012
Wanger, J., Clausen, J., Coates, A., Pedersen, O., Brusasco, V., Burgos, F., et al.
(2005). Standardisation of the measurement of lung volumes. Eur. Respir. J.
26:511. doi: 10.1183/09031936.05.00035005
Wegner, M., Helmich, I., Machado, S. E., Nardi, A., Arias-Carrion, O., and Budde,
H. (2014). Effects of exercise on anxiety and depression disorders: review of
meta-analyses and neurobiological mechanisms. CNS Neurol. Disord. Drug
Targets 13, 1002–1014. doi: 10.2174/1871527313666140612102841
Wrann, C. D., White, J. P., Salogiannnis, J., Laznik-Bogoslavski, D., Wu, J., Ma, D.,
et al. (2013). Exercise induces hippocampal BDNF through a PGC-1α/FNDC5
pathway. Cell Metab. 18, 649–659. doi: 10.1016/j.cmet.2013.09.008
Xu, B. (2013). BDNF (I) rising from exercise. Cell Metab. 18, 612–614.
doi: 10.1016/j.cmet.2013.10.008
Yan, Q., Feng, M., and Yan, S. (2005). Different expression of brain-
derived neurotrophic factor in the nucleus accumbens of alcohol-
preferring (P) and-nonpreferring (NP) rats. Brain Res. 1035, 215–218.
doi: 10.1016/j.brainres.2004.12.039
Yang, Y., Zhao, M., Zhang, Y., Shen, X., and Yuan, Y. (2016). Correlation of 5-
HTT, BDNF and NPSR1 gene polymorphisms with anxiety and depression
in asthmatic patients. Int. J. Mol. Med. 38, 65–74. doi: 10.3892/ijmm.
2016.2581
Zsuga, J., Biro, K., Papp, C., Tajti, G., and Gesztelyi, R. (2016a). The “proactive”
model of learning: integrative framework for model-free and model-based
reinforcement learning utilizing the associative learning-based proactive brain
concept. Behav. Neurosci. 130:6. doi: 10.1037/bne0000116
Zsuga, J., Biro, K., Tajti, G., Szilasi, M. E., Papp, C., Juhasz, B., et al. (2016b).
‘Proactive’use of cue-context congruence for building reinforcement learning’s
reward function. BMC Neurosci. 17:70. doi: 10.1186/s12868-016-0302-7
Zsuga, J., Tajti, G., Papp, C., Juhasz, B., and Gesztelyi, R. (2016c). FNDC5/irisin,
a molecular target for boosting reward-related learning and motivation. Med.
Hypotheses 90, 23–28. doi: 10.1016/j.mehy.2016.02.020
Zsuga, J., Török, J., Magyar, M. T., Valikovics, A., Gesztelyi, R.,
Lenkei, Á., et al. (2007). Dimethylarginines at the crossroad of
insulin resistance and atherosclerosis. Metab. Clin. Exp. 56, 394–399.
doi: 10.1016/j.metabol.2006.10.023
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Szilasi, Pak, Kardos, Varga, Seres, Mikaczo, Fodor, Szilasi, Tajti,
Papp, Gesztelyi and Zsuga. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 12 November 2017 | Volume 11 | Article 653
